Welcome to our dedicated page for PRF Technologies Ltd. news (Ticker: PRFX), a resource for investors and traders seeking the latest updates and insights on PRF Technologies Ltd. stock.
PainReform Ltd. (Nasdaq: PRFX) generates news across two main areas: specialty pharmaceutical development for post-surgical pain and ophthalmology, and AI-driven solar and energy analytics through its DeepSolar platform. Company updates often highlight progress in extended-release drug-delivery technologies and in advanced digital tools for managing solar assets.
On the pharmaceutical side, news items cover developments in PRF-110, PainReform’s oil-based ropivacaine formulation for localized post-operative analgesia, and the OcuRing™-K program acquired through its majority investment in LayerBio. Releases describe preclinical and clinical milestones for OcuRing-K, including Phase I safety data in cataract surgery patients and R&D assessments showing that the sustained-release matrix can incorporate multiple drug entities such as corticosteroids and NSAIDs. These updates provide insight into how the company is pursuing dropless, sustained-release approaches to post-cataract pain and inflammation management.
In parallel, DeepSolar-related news focuses on AI-based solar analytics and energy optimization. Coverage includes the development of DeepSolar Predict, an AI forecasting module for photovoltaic systems advanced within the NVIDIA Connect program, the launch of Smart TDD for solar technical due diligence, and progress on an automated reporting engine that consolidates operational data into tailored performance reports. PainReform has also reported on pilot and commercial engagements for DeepSolar, such as a 92MW project with Econergy Renewable Energy.
Investors and observers can use this news feed to follow regulatory and clinical steps for PainReform’s pharmaceutical candidates, as well as product launches, technology collaborations, and commercial milestones in its DeepSolar business. Regular updates provide context on how the company advances its dual focus on non-opiate pain management and renewable-energy analytics.
PainReform Ltd. (Nasdaq: PRFX) reported significant advancements towards launching Phase 3 clinical trials for PRF-110, targeting post-operative pain relief in bunionectomy surgery. With a strong cash position of $19.4 million as of March 31, 2021, the company is prepared for ongoing activities and future trials. Recent financial results show a net loss of $2.041 million for Q1 2021, reflecting a 57% increase from the previous year due to rising operational costs linked to clinical trial preparations. The firm remains optimistic about PRF-110's potential to reduce opioid reliance.
PainReform Ltd. (Nasdaq: PRFX) announced significant progress in its Phase 3 clinical trials for PRF-110. The company engaged Lotus Clinical Research for the bunionectomy surgery trial, set to begin mid-2021. Recent achievements include a $6 million private placement, enhancing its cash runway for key milestones. However, the company reported a net loss of $4.1 million for 2020, with substantial increases in R&D and administrative expenses. The cash position as of December 31, 2020, was $15.7 million, expected to fund operations into Q2 2022.
PainReform Ltd. (Nasdaq: PRFX) announced that CEO Ilan Hadar will present at the Inaugural Emerging Growth Virtual Conference from March 17-19, 2021. This presentation will be accessible to registered participants and later posted on PainReform’s website. The company specializes in reformulating established therapeutics, with its lead product, PRF-110, focusing on post-operative pain relief using a local anesthetic, ropivacaine. PRF-110 aims to provide extended analgesia through a unique delivery system, reducing the need for opiates.
PainReform Ltd. (Nasdaq: PRFX) announced a private placement to raise approximately $6.0 million by issuing 1,304,346 ordinary shares and warrants. The purchase price is set at $4.60 per share, with warrants allowing the purchase of an additional 652,173 shares. Closing is expected on March 10, 2021, pending customary conditions. Maxim Group LLC and Joseph Gunnar & Co., LLC are acting as placement agents. The securities will not be registered under the Securities Act and are offered only to accredited investors. This move highlights PainReform's strategy to secure funding for its pain relief product, PRF-110.
PainReform Ltd. (Nasdaq: PRFX), a clinical stage specialty pharmaceutical company, announced participation in the H.C. Wainwright BioConnect 2021 Conference, occurring virtually from January 11-14, 2021. A webcast of the presentation will be available on-demand starting January 11, 2021, at 6:00 a.m. ET, accessible for 90 days. PainReform's lead product, PRF-110, aims to enhance post-operative pain relief using a proprietary extended-release drug-delivery system, targeting the local anesthetic market with reduced opiate needs.
PainReform Ltd. (Nasdaq: PRFX) has appointed Rita Keynan as Vice President of Pharmaceutical Operations. With over 25 years in the pharmaceutical sector, Keynan has a solid background in drug development, overseeing all facets from early trials to NDA filings. Her prior role was with VYNE Therapeutics, managing a team focused on drug development. CEO Ilan Hadar expressed confidence in her capabilities as the company prepares for Phase 3 trials of their lead product, PRF-110, aimed at post-operative pain relief through an innovative drug-delivery system.
PainReform Ltd. (NasdaqCM:PRFX) announced the appointment of Lotus Clinical Research as its CRO for the upcoming Phase 3 trial of PRF-110. This trial will focus on patients undergoing bunionectomy and hernia repair operations. LCR is specialized in analgesic studies, with a history of approximately 350 trials resulting in over ten approvals. Previous Phase 2 results showed PRF-110 provided pain relief for up to 72 hours, outperforming ropivacaine's 2-6 hours. The CEO stated confidence in the trial's design, aiming to address the opioid crisis while demonstrating safer pain relief options.
PainReform Ltd. (NASDAQ:PRFX) has appointed Ilan Hadar as its new CEO, effective immediately. With over 20 years in the pharmaceutical sector, Hadar has led operations and developed products in the U.S. and Israel. His previous roles include serving as Country Manager and CFO at Foamix Pharmaceuticals and Finance Director at Pfizer. The appointment comes as PainReform prepares for pivotal Phase 3 trials for its lead product PRF-110, aimed at changing post-operative pain management by reducing reliance on opioids.
PainReform Ltd. (NASDAQ:PRFX) has appointed Dr. Ellen Baron to its Board of Directors, enhancing its leadership after a recent IPO. Dr. Baron brings over 20 years of experience in the healthcare and capital markets sectors, previously holding key positions at Outcome Capital LLC and Healthios Capital Markets. Her expertise in business development and clinical affairs will be pivotal as PainReform advances its PRF-110 drug through Phase 3 trials aimed at the post-operative pain relief market. The company is optimistic about its future growth potential, targeting a significant market opportunity.
PainReform Ltd. (NASDAQ:PRFX) has appointed Augustine Lawlor to its Board of Directors following its recent IPO. Lawlor, with extensive experience in the pharmaceutical sector, previously served as COO of Leap Therapeutics and held key positions at LeukoSite and Alpha-Beta Technologies. His expertise includes finance, business development, and mergers and acquisitions, making him a valuable addition as PainReform advances its lead product, PRF-110, through Phase 3 trials. This product aims to revolutionize post-operative pain management while potentially reducing reliance on opioids.